| Literature DB >> 28053591 |
Abdulaziz Al Odhayani1, Ayla Tourkmani1, Mohammed Alshehri1, Hala Alqahtani1, Adel Mishriky1.
Abstract
The elderly population is increasing throughout the globe, resulting in higher healthcare costs. Potential inappropriate medication (PIM) prescriptions are a major health problem affecting the elderly persons. Due to limited studies in PIM use in primary care and home healthcare in Saudi Arabia, we aim to examine the extent of PIM prescription for and use by elderly patients. This study was carried out with 798 elderly patients, arbitrarily selected from Prince Sultan Medical Military City through the patient register. The mean age of the patients were in the range of 75.2 ± 5.5; 37.8% were males and 62.2% were females. The elderly patients are affected majorly with diabetes (73.9%), hypertension (83.2%) and lipid abnormalities (73.8%). The maximum patients involved in this study were affected with lower hemoglobin levels i.e. 99.2%. Renal impairment was found in 64% and iron supplements were the most commonly used in 23.1%, followed by analgesics and opioids (17%). The 52.5% of participants were using one or more PIMs. Kidney was the only functions and had influence on prescribed decisions. This study indicates PIM is a concern in elderly patients attending clinics and home residents and commonly prescribed ones are atypical antipsychotics, iron overdose, benzodiazepines and opioids. Prescription of drug-drug interactions, cascades and inappropriate drug doses results in preventable adverse effects.Entities:
Keywords: Adverse effects; Elderly; Inappropriate; Medications; Prescribing
Year: 2016 PMID: 28053591 PMCID: PMC5198987 DOI: 10.1016/j.sjbs.2016.05.006
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 1319-562X Impact factor: 4.219
Age, sex and medical history of homecare and CDC patients.
| Total ( | Homecare ( | CDC ( | ||||||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |||
| Mean ± SD | 75.2 ± 5.5 | 75.8 ± 5.4 | 72.2 ± 5.0 | <0.001 | ||||
| Median (Q1–Q3) | 75 (71–79) | 76 (72–80) | 72 (68–76) | |||||
| Male | 302 | 37.8 | 238 | 35.9 | 64 | 47.4 | ||
| Female | 496 | 62.2 | 425 | 64.1 | 71 | 52.6 | 6.317 | 0.012 |
| Diabetes type 2 (DM2) | 590 | 73.9 | 458 | 69.1 | 132 | 97.8 | 47.933 | <0.001 |
| Hypertension (HTN) | 664 | 83.2 | 552 | 83.3 | 112 | 83.0 | 0.007 | 0.933 |
| Dyslipidaemia | 589 | 73.8 | 467 | 70.4 | 122 | 90.4 | 23.053 | <0.001 |
| Ischaemic heart disease (IHD) | 136 | 17.0 | 121 | 18.3 | 15 | 11.1 | 4.044 | 0.044 |
| Congestive heart failure (CHF) | 31 | 3.9 | 22 | 3.3 | 9 | 6.7 | 3.368 | 0.066 |
| Dementia | 50 | 6.3 | 49 | 7.4 | 1 | 0.7 | 8.445 | 0.004 |
| Parkinson’s disease | 37 | 4.6 | 36 | 5.4 | 1 | 0.7 | 5.578 | 0.018 |
| Seizure disorders | 37 | 4.6 | 37 | 5.6 | 0 | 0.0 | 7.900 | 0.005 |
| Psychiatric diseases | 193 | 24.2 | 188 | 28.4 | 5 | 3.7 | 37.175 | <0.001 |
| Renal function test abnormality | 511 | 64.0 | 417 | 62.9 | 94 | 80.3 | 13.397 | <0.001 |
| Liver function test abnormality | 5 | 0.6 | 3 | 0.2 | 2 | 1.5 | Fisher | 0.200 |
| Haemoglobin (Hb) abnormality | 792 | 99.2 | 657 | 99.1 | 135 | 100.0 | 1.231 | 0.267 |
Statistically significant at p < 0.05.
Figure 1Participants’ medical conditions.
Frequency of use of PIMs by medication group (n = 798).
| Frequency | Percentage | |
|---|---|---|
| Anticholinergics/muscle relaxants/antispasmodics | ||
| 1 | 39 | 4.9 |
| Antipsychotics | ||
| 1 | 61 | 7.6 |
| 2 | 8 | 1 |
| Antiepileptics | ||
| 1 | 0 | 0.0 |
| Sedative-hypnotics | ||
| 1 | 6 | 0.8 |
| Antihypertensives | ||
| 1 | 12 | 1.5 |
| Antidepressants | ||
| 1 | 17 | 2.1 |
| Skeletal muscle relaxants | ||
| 1 | 43 | 5.4 |
| Anti-infectives | ||
| 1 | 2 | 0.3 |
| Oral hypoglycaemics | ||
| 1 | 49 | 6.1 |
| Analgesics and opioids | ||
| 1 | 119 | 14.9 |
| 2 | 16 | 2 |
| 3 | 1 | 0.1 |
| Platelet aggregation inhibitors | ||
| 1 | 4 | 0.5 |
| Antiarrhythmics | ||
| 1 | 7 | 0.9 |
| Iron supplements | ||
| 1 | 184 | 23.1 |
Figure 2High-risk medications used by participants.
Total number of PIMs among participants (n = 798).
| Total No. of medications | Frequency | Percentage |
|---|---|---|
| 0 | 379 | 47.5 |
| 1 | 103 | 12.9 |
| 2 | 138 | 17.3 |
| 3 | 54 | 6.8 |
| 4 | 69 | 8.6 |
| 5 | 23 | 2.9 |
| 6 | 17 | 2.1 |
| 7 | 3 | 0.4 |
| 8 | 9 | 1.1 |
| 9 | 1 | 0.1 |
| 10 | 1 | 0.1 |
| 12 | 1 | 0.1 |
Comparison of homecare and CDC patients’ medication use.
| HHC ( | CDC ( | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| Oxybutynin | 8 | 1.2 | 0 | 0.0 | Fisher | 0.364 |
| Tolterodine | 13 | 2.0 | 0 | 0.0 | Fisher | 0.141 |
| Chlorpheniramine | 11 | 1.7 | 0 | 0.0 | Fisher | 0.227 |
| Hydroxyzine | 2 | 0.3 | 0 | 0.0 | Fisher | 1.000 |
| Hyoscyamine | 1 | 0.2 | 0 | 0.0 | Fisher | 1.000 |
| Scopolamine | 2 | 0.3 | 2 | 1.5 | Fisher | 0.135 |
| Quetiapine | 29 | 4.4 | 1 | 0.7 | 4.092 | 0.043 |
| Haloperidol | 5 | 0.8 | 0 | 0.0 | Fisher | 0.596 |
| Olanzapine | 3 | 0.5 | 0 | 0.0 | Fisher | 1.000 |
| Risperidone | 39 | 5.9 | 0 | 0.0 | 8.349 | 0.004 |
| Diazepam | 3 | 0.5 | 0 | 0.0 | Fisher | 1.000 |
| Lorazepam | 3 | 0.5 | 0 | 0.0 | Fisher | 1.000 |
| Antihypertensives: | ||||||
| Methyldopa | 1 | 0.2 | 1 | 0.7 | Fisher | 0.310 |
| Spironolactone > 25 mg | 9 | 1.4 | 1 | 0.7 | Fisher | 1.000 |
| Fluoxetine | 4 | 0.6 | 0 | 0.0 | Fisher | 1.000 |
| Clomipramine | 1 | 0.2 | 0 | 0.0 | Fisher | 1.000 |
| Amitriptyline | 11 | 1.7 | 1 | 0.7 | Fisher | 0.702 |
| Tizanidine | 38 | 5.7 | 2 | 1.5 | 4.255 | 0.039 |
| Baclofen | 3 | 0.5 | 0 | 0.0 | Fisher | 1.000 |
| Nitrofurantoin | 2 | 0.3 | 0 | 0.0 | Fisher | 1.000 |
| Glibenclamide | 42 | 6.3 | 7 | 5.2 | 0.257 | 0.612 |
| Ibuprofen | 10 | 1.5 | 2 | 1.5 | Fisher | 1.000 |
| Diclofenac | 36 | 5.4 | 6 | 4.4 | 0.218 | 0.640 |
| Paracetamol combination | 80 | 12.1 | 18 | 13.3 | 0.167 | 0.683 |
| Decongestant | 2 | 0.3 | 0 | 0.0 | Fisher | 1.000 |
| Dipyridamole | 4 | 0.6 | 0 | 0.0 | Fisher | 1.000 |
| Digoxin > 125 mcg | 7 | 1.1 | 0 | 0.0 | Fisher | 0.609 |
| Ferrous sulphate > 325 mg | 175 | 26.4 | 9 | 6.7 | 24.607 | <0.001 |
Statistically significant at p < 0.05.
Comparison of the number of PIM groups used, based on renal function tests (RFT).
| Normal Renal Function Test (n = 269) | Abnormal Renal Function Test (n = 511) | Mann–Whitney ( | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Min | Max | Median | Q1 | Q3 | Mean | SD | Min | Max | Median | Q1 | Q3 | |||
| Anticholinergics/muscle relaxants/antispasmodics | 0.1 | 0.2 | 0 | 1 | 0 | 0 | 0 | 0.0 | 0.2 | 0 | 1 | 0 | 0 | 0 | −1.226 | 0.220 |
| Antipsychotics | 0.1 | 0.4 | 0 | 2 | 0 | 0 | 0 | 0.1 | 0.3 | 0 | 2 | 0 | 0 | 0 | −1.680 | 0.093 |
| Sedative-hypnotics | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | −0.802 | 0.423 |
| Antihypertensives | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | −0.527 | 0.598 |
| Antidepressants | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | −0.071 | 0.944 |
| Skeletal muscle relaxants | 0.1 | 0.2 | 0 | 1 | 0 | 0 | 0 | 0.1 | 0.2 | 0 | 1 | 0 | 0 | 0 | −0.056 | 0.955 |
| Anti-infectives | 0.0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | −1.027 | 0.305 |
| Oral hypoglycaemics | 0.0 | 0.2 | 0 | 1 | 0 | 0 | 0 | 0.1 | 0.3 | 0 | 1 | 0 | 0 | 0 | −1.520 | 0.129 |
| Analgesics and opioids | 0.2 | 0.5 | 0 | 2 | 0 | 0 | 0 | 0.2 | 0.5 | 0 | 3 | 0 | 0 | 0 | −1.139 | 0.255 |
| Platelet aggregation–inhibitors | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | 0.0 | 0.0 | 0 | 1 | 0 | 0 | 0 | −1.708 | 0.088 |
| Antiarrhythmics | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | 0.0 | 0.1 | 0 | 1 | 0 | 0 | 0 | −1.266 | 0.206 |
| Iron supplements | 0.4 | 0.5 | 0 | 1 | 0 | 0 | 1 | 0.2 | 0.4 | 0 | 1 | 0 | 0 | 0 | −6.909 | <0.001 |
| Total No. medications | 1.7 | 2.0 | 0 | 10 | 1 | 0 | 3 | 1.3 | 1.8 | 0 | 12 | 0 | 0 | 2 | −3.209 | 0.001 |
Statistically significant at p < 0.05.